BioSpace News Archive

Healthcare laboratory informatics is an information technology-based application employed in various healthcare organizations to optimize and make efficient the laboratory operations.

According to the report, the global recombinant factor C assay market was valued at ~US$ 13 Mn in 2018 and is projected to expand at a considerable CAGR during the forecast period.

Cell therapy is also popularly known as cellular therapy or cytotherapy. This therapy can be described as a type of biotherapy mainly utilized for the development of various drugs and therapeutic strategies that are cells based.

The global knee cartilage repair market was valued at approximately US$ 4.0 Bn in 2017.

According to the report, the global nasopharyngeal swabs market was valued at ~US$ 103 Mn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030.

According to the report, the global oral thin films market was valued at US$ 2.6 Bn in 2019.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS), today reported its third quarter 2021 operating and financial results.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), today announced financial results for the three and nine months ended September 30, 2021.

Ardelyx, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies London Healthcare Conference, which is taking place virtually and in-person on November 16 – 19, 2021.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that a study published in Nature Medicine reinforces the benefits of using the Guardant360® liquid biopsy test to help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC).